nach oben

Endocrine

Erschienen in:

01.10.2019 | Review

Novel thyroxine formulations: a further step toward precision medicine

verfasst von: Camilla Virili, Pierpaolo Trimboli, Marco Centanni

Erschienen in: Endocrine | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Levothyroxine (T4) is a critical-dose drug, because little variations in the blood concentration may cause treatment failure as well as iatrogenic thyrotoxicosis. Despite the dose response of this drug being more carefully titrated nowadays, several papers still report that a significant fraction of patients treated with levothyroxine demonstrate a TSH which is not on target. Moreover, some widespread gastrointestinal disorders as well as interfering drugs and foods may cause the “refractoriness” of a significant number of patients to an expected dose of thyroxine. The increasing awareness of the mechanisms interfering with the oral thyroid hormone bioavailability and the body of evidence regarding the complexity of treatment in certain classes of patients prompted pharmaceutical research to identify new hormonal formulations to optimize the performance of this drug. In this brief review, the progression of the scientific knowledge of novel T4 formulations use has been analyzed.

C.R. Harington, G. Barger, Chemistry of thyroxine: constitution and synthesis of thyroxine. Biochem. J. 21, 169–183 (1927)CrossRef

J.V. Hennessey, The emergence of levothyroxine as a treatment for hypothyroidism. Endocrine 55, 6–18 (2017)CrossRef

J. Jonklaas, A.C. Bianco, A.J. Bauer, K.D. Burman, A.R. Cappola, F.S. Celi, D.S. Cooper, B.W. Kim, R.P. Peeters, M.S. Rosenthal, A.M. Sawka, American Thyroid Association Task Force on Thyroid Hormone Replacement, Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid 24, 1670–1751 (2014)CrossRef

https://www.statista.com/statistics/780284/levothyroxine-prescriptions-number-in-the-us/ Accessed 6 May 2019

R.B. Shah, J.S. Collier, V.A. Sayeed, A. Bryant, M.J. Habib, M.A. Khan, Tablet splitting of a narrow therapeutic index drug: a case with levothyroxine sodium. AAPS PharmSciTech 11, 1359–1367 (2010)CrossRef

B. Biondi, D.S. Cooper, The clinical significance of subclinical thyroid dysfunction. Endocr. Rev. 29, 76–131 (2008). https://doi.org/10.1210/er.2006-0043 CrossRefPubMed

B. Biondi, D.S. Cooper, Subclinical hyperthyroidism. N. Engl. J. Med. 378, 2411–2419 (2018). https://doi.org/10.1056/NEJMcp1709318 CrossRefPubMed

B. Biondi, L. Wartofsky, Treatment with thyroid hormone. Endocr. Rev. 35, 433–512 (2014). https://doi.org/10.1210/er.2013-1083 CrossRefPubMed

F. Santini, A. Pinchera, A. Marsili, G. Ceccarini, M.G. Castagna, R. Valeriano, M. Giannetti, D. Taddei, R. Centoni, G. Scartabelli, T. Rago, C. Mammoli, R. Elisei, P. Vitti, Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J. Clin. Endocrinol. Metab. 90, 124–127 (2005)CrossRef

10.

V. Eligar, P.N. Taylor, O.E. Okosieme, G.P. Leese, C.M. Dayan, Thyroxine replacement: a clinical endocrinologist’s viewpoint. Ann. Clin. Biochem. 53, 421–433 (2016). https://doi.org/10.1177/0004563216642255 CrossRefPubMed

11.

C. Cappelli, R. Castello, F. Marini, A. Paoletta, M. Marchetti, M. Saullo, A. Cristiano, I. Pirola, E. Gandossi, A. Ferlin, M. Castellano, Adherence to levothyroxine treatment among patients with hypothyroidism: a Northeastern Italian Survey. Front Endocrinol. 9, 699 (2018). https://doi.org/10.3389/fendo.2018.00699 CrossRef

12.

H.M. Robertson, A.K. Narayanaswamy, O. Pereira, S.A. Copland, R. Herriot, A.W. McKinlay, J.S. Bevan, P. Abraham, Factors contributing to high levothyroxine doses in primary hypothyroidism: an interventional audit of a large community database. Thyroid 24, 1765–1771 (2014). https://doi.org/10.1089/thy.2013.0661 CrossRefPubMed

13.

N. Van Wilder, B. Bravenboer, S. Herremans, N. Vanderbruggen, B. Velkeniers, Pseudomalabsorption of levothyroxine: a challenge for the endocrinologist in the treatment of hypothyroidism. Eur. Thyroid J. 6, 52–56 (2017). https://doi.org/10.1159/000452489 CrossRefPubMed

14.

M.T. Hays, Localization of human thyroxine absorption. Thyroid 1, 241–248 (1991)CrossRef

15.

S.S. Jambhekar, P.J. Breen, Drug dissolution: significance of physicochemical properties and physiological conditions. Drug Discov. Today 18, 1173–1184 (2013)CrossRef

16.

D. Pabla, F. Akhlaghi, H. Zia, A comparative pH-dissolution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry. Eur. J. Pharm. Biopharm. 72, 105–110 (2009)CrossRef

17.

M. Centanni, L. Gargano, G. Canettieri, N. Viceconti, A. Franchi, G. Delle Fave, B. Annibale, Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N. Engl. J. Med. 354, 1787–1795 (2006)CrossRef

18.

M. Cellini, M.G. Santaguida, C. Virili, S. Capriello, N. Brusca, L. Gargano, M. Centanni, Hashimoto’s thyroiditis and autoimmune gastritis. Front. Endocrinol. 8, 92 (2017)CrossRef

19.

C. Virili, A. Antonelli, M.G. Santaguida, S. Benvenga, M. Centanni, Gastrointestinal malabsorption of thyroxine. Endocr. Rev. 40, 118–136 (2019). https://doi.org/10.1210/er.2018-00168 CrossRefPubMed

20.

K.W. Wenzel, H.E. Kirschsieper, Aspects of the absorption of oral L-thyroxine in normal man. Metabolism 26, 1–8 (1977)CrossRef

21.

T.G. Bach-Huynh, B. Nayak, J. Loh, S. Soldin, J. Jonklaas, Timing of levothyroxine administration affects serum thyrotropin concentration. J. Clin. Endocrinol. Metab. 94, 3905–3912 (2009)CrossRef

22.

A. Tortora, D. La Sala, M. Vitale, Switch from tablet levothyroxine to oral solution resolved reduced absorption by intestinal parasitosis. Endocrinol. Diabetes Metab. Case Rep. https://doi.org/10.1530/EDM-19-0026

23.

C. Virili, G. Bassotti, M.G. Santaguida, R. Iuorio, S.C. Del Duca, V. Mercuri, A. Picarelli, P. Gargiulo, L. Gargano, M. Centanni, Atypical celiac disease as cause of increased need for thyroxine: a systematic study. J. Clin. Endocrinol. Metab. 97, E419–E422 (2012). https://doi.org/10.1210/jc.2011-1851 CrossRefPubMed

24.

M. Cellini, M.G. Santaguida, I. Gatto, C. Virili, S.C. Del Duca, N. Brusca, S. Capriello, L. Gargano, M. Centanni, Systematic appraisal of lactose intolerance as cause of increased need for oral thyroxine. J. Clin. Endocrinol. Metab. 99, E1454–E1458 (2014). https://doi.org/10.1210/jc.2014-1217 CrossRefPubMed

25.

C. Virili, M. Centanni, Does microbiota composition affect thyroid homeostasis? Endocrine 49, 583–587 (2015)CrossRef

26.

C. Virili, M. Centanni, “With a little help from my friends”—the role of microbiota in thyroid hormone metabolism and enterohepatic recycling. Mol. Cell Endocrinol. 458, 39–43 (2017)CrossRef

27.

L.S. Ward, The difficult patient: drug interaction and the influence of concomitant diseases on the treatment of hypothyroidism. Arq. Bras. Endocrinol. Metabol. 54, 435–442 (2010)CrossRef

28.

M. Centanni, S. Benvenga, I. Sachmechi, Diagnosis and management of treatment-refractory hypothyroidism: an expert consensus report. J. Endocrinol. Investig. 40, 1289–1301 (2017). https://doi.org/10.1007/s40618-017-0706-y CrossRef

29.

C.S. Yue, C. Scarsi, M.P. Ducharme, Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. Arzneimittelforschung 62, 631–636 (2012). https://doi.org/10.1055/s-0032-1329951 CrossRefPubMed

30.

A. Cassio, S. Monti, A. Rizzello, I. Bettocchi, F. Baronio, G. D’Addabbo, M.O. Bal, A. Balsamo, Comparison between liquid and tablet formulations of levothyroxine in the initial treatment of congenital hypothyroidism. J. Pediatr. 162, 1264–1269 (2013). https://doi.org/10.1016/j.jpeds.2012.11.070 CrossRefPubMed

31.

E. Peroni, M.C. Vigone, S. Mora, L.A. Bassi, C. Pozzi, A. Passoni, G. Weber, Congenital hypothyroidism treatment in infants: a comparative study between liquid and tablet formulations of levothyroxine. Horm. Res. Paediatr. 81, 50–54 (2014). https://doi.org/10.1159/000356047 CrossRefPubMed

32.

I. Pirola, L. Daffini, E. Gandossi, D. Lombardi, A. Formenti, M. Castellano, C. Cappelli, Comparison between liquid and tablet levothyroxine formulations in patients treated through enteral feeding tube. J. Endocrinol. Investig. 37, 583–587 (2014). https://doi.org/10.1007/s40618-014-0082-9 CrossRef

33.

C. Cappelli, I. Pirola, L. Daffini, A. Formenti, C. Iacobello, A. Cristiano, E. Gandossi, E. Agabiti Rosei, M. Castellano, A double-blind placebo-controlled trial of liquid thyroxine ingested at breakfast: results of the TICO study. Thyroid 26, 197–202 (2016). https://doi.org/10.1089/thy.2015.0422 CrossRefPubMed

34.

I. Pirola, E. Gandossi, D. Brancato, F. Marini, A. Cristiano, A. Delbarba, B. Agosti, M. Castellano, C. Cappelli, TSH evaluation in hypothyroid patients assuming liquid levothyroxine at breakfast or 30 min before breakfast. J. Endocrinol. Investig. 41, 1301–1306 (2018). https://doi.org/10.1007/s40618-018-0867-3 CrossRef

35.

S. Morelli, G. Reboldi, S. Moretti, E. Menicali., N. Avenia., E. Puxeddu, Timing of breakfast does not influence therapeutic efficacy of liquid levothyroxine formulation. Endocrine 52, 571–578 (2015). https://doi.org/10.1007/s12020-015-0788-2 CrossRefPubMed

36.

R. Guglielmi, F. Grimaldi, R. Negro, A. Frasoldati, I. Misischi, F. Graziano, C. Cipri, E. Guastamacchia, V. Triggiani, E. Papini, Shift from levothyroxine tablets to liquid formulation at breakfast improves quality of life of hypothyroid patients. Endocr. Metab. Immune Disord. Drug Targets 18, 235–240 (2018)CrossRef

37.

M. Giusti, L. Mortara, N. Machello, E. Monti, G. Pera, M. Marenzana, Utility of a liquid formulation of levo-thyroxine in differentiated thyroid cancer patients. Drug Res. 65, 332–336 (2014)CrossRef

38.

D. Ribichini, G. Fiorini, A. Repaci, V. Castelli, L. Gatta, D. Vaira, R. Pasquali, Tablet and oral liquid L-thyroxine formulation in the treatment of naïve hypothyroid patients with Helicobacter pylori infection. Endocrine 57, 394–401 (2017). https://doi.org/10.1007/s12020-016-1167-3 CrossRefPubMed

39.

P. Fallahi, S.M. Ferrari, I. Ruffilli, A. Antonelli, Reversible normalisation of serum TSH levels in patients with autoimmune atrophic gastritis who received L-T4 in tablet form after switching to an oral liquid formulation: a case series. BMC Gastroenterol. 24, 16–22 (2016). https://doi.org/10.1186/s12876-016-0439-y CrossRef

40.

P. Fallahi, S.M. Ferrari, S. Marchi, N. De Bortoli, I. Ruffilli, A. Antonelli, Patients with lactose intolerance absorb liquid levothyroxine better than tablet levothyroxine. Endocrine 57, 175–178 (2017). https://doi.org/10.1007/s12020-016-1090-7 CrossRefPubMed

41.

S. Benvenga, G. Capodicasa, S. Perelli, S.M. Ferrari, P. Fallahi, A. Antonelli, Increased requirement of replacement doses of levothyroxine caused by liver cirrhosis. Front. Endocrinol. 9, 150 (2018). https://doi.org/10.3389/fendo.2018.00150 CrossRef

42.

C. Hommel, E. Delgrange, Resistance to levothyroxine in a bariatric surgery patient: an indication for liquid formulation? Acta Clin. Belg. 72, 72–75 (2017). https://doi.org/10.1080/17843286.2016.1196861 CrossRefPubMed

43.

I. Pirola, A.M. Formenti, E. Gandossi, F. Mittempergher, C. Casella, B. Agosti, C. Cappelli, Oral liquid L-thyroxine (L-T4) may be better absorbed compared to L-T4 tablets following bariatric surgery. Obes. Surg. 23, 1493–1496 (2013). https://doi.org/10.1007/s11695-013-1015-y CrossRefPubMedPubMedCentral

44.

P. Fallahi, S.M. Ferrari, S. Camastra, U. Politti, I. Ruffilli, R. Vita, G. Navarra, S. Benvenga, A. Antonelli, TSH normalization in bariatric surgery patients after the switch from L-thyroxine in tablet to an oral liquid formulation. Obes. Surg. 27, 78–82 (2017). https://doi.org/10.1007/s11695-016-2247-4 CrossRefPubMed

45.

R.A. Payne, The epidemiology of polypharmacy. Clin. Med. 16, 465–469 (2016)CrossRef

46.

R. Vita, G. Saraceno, F. Trimarchi, S. Benvenga, Switching levothyroxine from the tablet to the oral solution formulation corrects the impaired absorption of levothyroxine induced by proton-pump inhibitors. J. Clin. Endocrinol. Metab. 99, 4481–4486 (2014). https://doi.org/10.1210/jc.2014-2684 CrossRefPubMed

47.

D. Brancato, A. Scorsone, G. Saura, L. Ferrara, A. Di Noto, V. Aiello, M. Fleres, V. Provenzano, Comparison of TSH levels with liquid formulation versus tablet formulations of levothyroxine in the treatment of adult hypothyroidism. Endocr. Pract. 20, 657–662 (2014). https://doi.org/10.4158/EP13418.OR CrossRefPubMed

48.

S. Benvenga, F. Di Bari, R. Vita, Undertreated hypothyroidism due to calcium or iron supplementation corrected by oral liquid levothyroxine. Endocrine 56, 138–145 (2017). https://doi.org/10.1007/s12020-017-1244-2 CrossRefPubMed

49.

E. Morini, A. Catalano, A. Lasco, N. Morabito, S. Benvenga, In thyroxine-replaced hypothyroid postmenopausal women under simultaneous calcium supplementation, switch to oral liquid or softgel capsule L-thyroxine ensures lower serum TSH levels and favorable effects on blood pressure, total cholesterolemia and glycemia. Endocrine. https://doi.org/10.1007/s12020-019-01908-x.

50.

R. Vita, F. Di Bari, S. Benvenga, Oral liquid levothyroxine solves the problem of tablet levothyroxine malabsorption due to concomitant intake of multiple drugs. Expert Opin. Drug Deliv. 14, 467–472 (2017). https://doi.org/10.1080/17425247.2017.1290604 CrossRefPubMed

51.

R. Ferrara, V. Ientile, V. Arcoraci, C. Ferrajolo, C. Piccinni, A. Fontana, S. Benvenga, G. Trifirò, Treatment pattern and frequency of serum TSH measurement in users of different levothyroxine formulations: a population-based study during the years 2009–2015. Endocrine 58, 143–152 (2017). https://doi.org/10.1007/s12020-017-1242-4 CrossRefPubMed

52.

C. Cappelli, I. Pirola, L. Daffini, E. Gandossi, B. Agosti, M. Castellano, Thyroid hormonal profile in elderly patients treated with two different levothyroxine formulations: a single institute survey. Eur. Geriatr. Med. 5, 382–385 (2014)CrossRef

53.

C. Cappelli, R. Negro, I. Pirola, E. Gandossi, B. Agosti, M. Castellano, Levothyroxine liquid solution versus tablet form for replacement treatment in pregnant women. Gynecol. Endocrinol. 20, 1–3 (2015)

54.

P. Fallahi, S.M. Ferrari, A. Antonelli, Oral L-thyroxine liquid versus tablet in patients with hypothyroidism without malabsorption: a prospective study. Endocrine 52, 597–601 (2016). https://doi.org/10.1007/s12020-015-0836-y CrossRefPubMed

55.

R. Negro, R. Valcavi, D. Agrimi, K.A. Toulis, Levothyroxine liquid solution versus tablet for replacement treatment in hypothyroid patients. Endocr. Pract. 20, 901–906 (2014). https://doi.org/10.4158/EP13378.OR CrossRefPubMed

56.

P. Fallahi, S.M. Ferrari, A. Antonelli, In patients with subclinical hypothyroidism while in therapy with tablet L-T4, the liquid L-T4 formulation is more effective in restoring euthyroidism. Endocr. Pract. 23, 170–174 (2017). https://doi.org/10.4158/EP161545.OR CrossRefPubMed

57.

P. Fallahi, S.M. Ferrari, G. Materazzi, F. Ragusa, I. Ruffilli, A. Patrizio, P. Miccoli, A. Antonelli, Oral L-thyroxine liquid versus tablet in patients submitted to total thyroidectomy for thyroid cancer (without malabsorption): a prospective study. Laryngoscope Investig. Otolaryngol. 3, 405–408 (2018). https://doi.org/10.1002/lio2.186 CrossRefPubMedPubMedCentral

58.

C. Peirce, S. Ippolito, A. Lanas, M. Pesce, G. Pontieri, D. Arpaia, G. Sarnelli, B. Biondi, Treatment of refractory and severe hypothyroidism with sublingual levothyroxine in liquid formulation. Endocrine 60, 193–196 (2018). https://doi.org/10.1007/s12020-017-1367-5 CrossRefPubMed

59.

S. Benvenga, F.Di Bari, Intestinal absorption and buccal absorption of liquid levothyroxine. Endocrine 58, 591–594 (2017). https://doi.org/10.1007/s12020-017-1250-4 CrossRefPubMed

60.

C. Virili, L. Giovanella, P. Fallahi, A. Antonelli, M.G. Santaguida, M. Centanni, P. Trimboli, Levothyroxine therapy: changes of TSH levels by switching patients from tablet to liquid formulation. a systematic review and meta-analysis. Front Endocrinol. 9, 10 (2018). https://doi.org/10.3389/fendo.2018.00010 CrossRef

61.

I. Laurent, S. Tang, M. Astère, K.R. Wang, S. Deng, L. Xiao, Q.F. Li, Liquid L-thyroxine versus tablet L-thyroxine in patients on L- thyroxine replacement or suppressive therapy: a meta-analysis. Endocrine 61, 28–35 (2018). https://doi.org/10.1007/s12020-018-1574-8 CrossRefPubMed

62.

R. Vita, P. Fallahi, A. Antonelli, S. Benvenga, The administration of L-thyroxine as softgel capsule or liquid solution. Expert Opin. Drug Deliv. 11, 1103–1111 (2014)CrossRef

63.

G. Fiorini, D. Ribichini, R. Pasquali, D. Vaira, In vivo dissolution of levothyroxine softgel capsules. Intern. Emerg. Med. 11, 1151–1152 (2016)CrossRef

64.

P. Colucci, P. D’Angelo, G. Mautone, C. Scarsi, M.P. Ducharme, Pharmacokinetic equivalence of a levothyroxine sodium soft capsule manufactured using the new food and drug administration potency guidelines in healthy volunteers under fasting conditions. Ther. Drug Monit. 33, 355–361 (2011). https://doi.org/10.1097/FTD.0b013e318217b69f CrossRefPubMed

65.

C. Seng Yue, S. Benvenga, C. Scarsi, L. Loprete, M.P. Ducharme, When bioequivalence in healthy volunteers may not translate to bioequivalence in patients: differential effects of increased gastric pH on the pharmacokinetics of levothyroxine capsules and tablets. J. Pharm. Pharm. Sci. 18, 844–855 (2015)CrossRef

66.

R. Vita, S. Benvenga, Tablet levothyroxine (L-T4) malabsorption induced by proton pump inhibitor; a problem that was solved by switching to L-T4 in softgel capsule. Endocr. Pract. 20, e38–e41 (2014)CrossRef

67.

M.G. Santaguida, C. Virili, S.C. Duca, M. Cellini, I. Gatto, N. Brusca, C. De Vito, L. Gargano, M. Centanni, Thyroxine softgel capsule in patients with gastric-related T4 malabsorption. Endocrine 49, 51–57 (2015). https://doi.org/10.1007/s12020-014-0476-7 CrossRefPubMed

68.

V. Di Donna, R.M. Paragliola, C. de Waure, G. Papi, A. Pontecorvi, S.M. Corsello, Is levothyroxine requirement the same for tablet and softgel formulations? Endocrine 59, 458–460 (2018). https://doi.org/10.1007/s12020-017-1311-8 CrossRefPubMed

69.

S. Benvenga, G. Capodicasa, S. Perelli, l-thyroxine in an oral liquid or softgel formulation ensures more normal serum levels of free T4 in patients with central hypothyroidism. Front. Endocrinol. 8, 321 (2017). https://doi.org/10.3389/fendo.2017.00321 CrossRef

70.

P.J. Kim, I. Sachmechi, Levothyroxine malabsorption induced by diabetic gastroparesis exacerbated during pregnancies: effect of intramuscular levothyroxine injections and levothyroxine softgel capsules. AACE Clin. Case Rep. 1, e73–e78 (2015)CrossRef

71.

D.P. Reardon, P.S. Yoo, Levothyroxine tablet malabsorption associated with gastroparesis corrected with gelatin capsule formulation. Case Rep. Endocrinol. 2016, 1316724 (2016). https://doi.org/10.1155/2016/1316724 CrossRefPubMedPubMedCentral

72.

F.R. Ernst, W. Sandulli, R. Elmor, J. Welstead, A.B. Sterman, M. Lavan, Retrospective study of patients switched from tablet formulations to a gel cap formulation of levothyroxine: results of the CONTROL Switch Study. Drugs R. D. 17, 103–115 (2017). https://doi.org/10.1007/s40268-016-0150-z CrossRefPubMed

73.

S. Benvenga, L. Bartolone, S. Squadrito, F. Lo Giudice, F. Trimarchi, Delayed intestinal absorption of levothyroxine. Thyroid 5, 249–253 (1995)CrossRef

74.

M. Centanni, Thyroxine treatment: absorption, malabsorption, and novel therapeutic approaches. Endocrine 43, 8–9 (2013). https://doi.org/10.1007/s12020-012-9814-9 CrossRefPubMed

75.

C. Cappelli, I. Pirola, E. Gandossi, A. Cristiano, L. Daffini, B. Agosti, C. Casella, M. Castellano, Thyroid hormone profile in patients ingesting softgel capsule or liquid levothyroxine formulations with breakfast. Int J. Endocrinol. 2016, 9043450 (2016). https://doi.org/10.1155/2016/9043450 CrossRefPubMedPubMedCentral

76.

P. Trimboli, C. Virili, M. Centanni, L. Giovanella, Thyroxine treatment with softgel capsule formulation: usefulness in hypothyroid patients without malabsorption. Front Endocrinol. 9, 118 (2018). https://doi.org/10.3389/fendo.2018.00118 CrossRef

77.

R. Vita, G. Saraceno, F. Trimarchi, S. Benvenga, A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations. Endocrine 43, 154–160 (2013). https://doi.org/10.1007/s12020012-9772-2 CrossRefPubMed

78.

E. Messina, F. Ferraù, S. Cannavò, Oral mucositis induced by treatment with softgel formulation of levothyroxine. Endocrine 59, 226–227 (2018). https://doi.org/10.1007/s12020-017-1312-7 CrossRefPubMed

Titel: Novel thyroxine formulations: a further step toward precision medicine
verfasst von: Camilla Virili
Pierpaolo Trimboli
Marco Centanni
Publikationsdatum: 01.10.2019
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 1/2019
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-019-02049-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

T4 + T3 combination therapy: any progress?

Thyroid hormone therapy: past, present, and future

Thyroxine and treatment of hypothyroidism: seven decades of experience

Novel uses of thyroid hormones in cardiovascular conditions

Thyroid hormone therapy of hypothyroidism in pregnancy